115 related articles for article (PubMed ID: 35183243)
1. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
[TBL] [Abstract][Full Text] [Related]
2. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.
Gaillard DHK; Lof P; Sistermans EA; Mokveld T; Horlings HM; Mom CH; Reinders MJT; Amant F; van den Broek D; Wessels LFA; Lok CAR; ;
Int J Gynecol Cancer; 2024 May; 34(5):713-721. PubMed ID: 38388177
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
[TBL] [Abstract][Full Text] [Related]
6. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.
Pal R; Choudhury T; Ghosh M; Vernakar M; Nath P; Nasare VD
Clin Transl Oncol; 2024 Jul; 26(7):1716-1724. PubMed ID: 38472557
[TBL] [Abstract][Full Text] [Related]
7. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer.
Liu C; Eng C; Shen J; Lu Y; Takata Y; Mehdizadeh A; Chang GJ; Rodriguez-Bigas MA; Li Y; Chang P; Mao Y; Hassan MM; Wang F; Li D
Oncotarget; 2016 Nov; 7(46):76250-76260. PubMed ID: 27788488
[TBL] [Abstract][Full Text] [Related]
8. Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass.
Buas MF; Drescher CW; Urban N; Li CI; Bettcher L; Hait NC; Moysich KB; Odunsi K; Raftery D; Yan L
Sci Rep; 2021 Sep; 11(1):18156. PubMed ID: 34518593
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis.
Zhang W; Lai Z; Liang X; Yuan Z; Yuan Y; Wang Z; Peng P; Xia L; Yang X; Li Z
Clin Chim Acta; 2024 Jun; 560():119734. PubMed ID: 38777245
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
Kanlikilicer P; Rashed MH; Bayraktar R; Mitra R; Ivan C; Aslan B; Zhang X; Filant J; Silva AM; Rodriguez-Aguayo C; Bayraktar E; Pichler M; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
Cancer Res; 2016 Dec; 76(24):7194-7207. PubMed ID: 27742688
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
Terry KL; Schock H; Fortner RT; Hüsing A; Fichorova RN; Yamamoto HS; Vitonis AF; Johnson T; Overvad K; Tjønneland A; Boutron-Ruault MC; Mesrine S; Severi G; Dossus L; Rinaldi S; Boeing H; Benetou V; Lagiou P; Trichopoulou A; Krogh V; Kuhn E; Panico S; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Gram IT; Weiderpass E; Duell EJ; Sanchez MJ; Ardanaz E; Etxezarreta N; Navarro C; Idahl A; Lundin E; Jirström K; Manjer J; Wareham NJ; Khaw KT; Byrne KS; Travis RC; Gunter MJ; Merritt MA; Riboli E; Cramer DW; Kaaks R
Clin Cancer Res; 2016 Sep; 22(18):4664-75. PubMed ID: 27060155
[TBL] [Abstract][Full Text] [Related]
12. Extraction and identification of exosomes from three different sources of human ovarian granulosa cells and analysis of their differential miRNA expression profiles.
Li X; Gao T; Ma X; Zhong J; Qin L; Nian Y; Wang X; Luo Y
J Assist Reprod Genet; 2024 May; 41(5):1371-1385. PubMed ID: 38492155
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA 421 induces the formation of high-invasive cell subsets of ovarian cancer from low-invasive cell subsets mediated by exosomes by activating the PI3K/AKT pathway.
Meng Q; Zheng W; Jiao R; Cui R; Deng Y; Liu R; Wang J; Bai H
Am J Cancer Res; 2024; 14(5):2643-2660. PubMed ID: 38859864
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of exosomal miRNAs and their related genes in head and neck cancer patients.
Rizwan M; Mahjabeen I; Ashraf NS; Arshad M; Haris MS; Kayani MA
Future Oncol; 2024 May; ():1-15. PubMed ID: 38861304
[TBL] [Abstract][Full Text] [Related]
15. Electrochemical Sensor for the Detection and Accurate Early Diagnosis of Ovarian Cancer.
Ge F; Ding W; Han C; Zhang L; Liu Q; Zhao J; Luo Z; Jia C; Qu P; Zhang L
ACS Sens; 2024 May; ():. PubMed ID: 38776471
[TBL] [Abstract][Full Text] [Related]
16. Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis.
Li H; Sui T; Chen X; Gu Y; Luo X; Liu Y; He Q
Am J Cancer Res; 2024; 14(4):1904-1913. PubMed ID: 38726286
[TBL] [Abstract][Full Text] [Related]
17. In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer.
Kaur M; MacPherson CR; Schmeier S; Narasimhan K; Choolani M; Bajic VB
BMC Syst Biol; 2011 Sep; 5():144. PubMed ID: 21923952
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features associated to MiRNA-195 expression in patients with breast cancer: Evidence of a potential biomarker.
Nadeem F; Hanif M; Ahmed A; Jamal Q; Khan A
Pak J Med Sci; 2017; 33(5):1242-1247. PubMed ID: 29142572
[TBL] [Abstract][Full Text] [Related]
19. An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection.
Bhadra M; Sachan M
Heliyon; 2024 May; 10(9):e30328. PubMed ID: 38707279
[TBL] [Abstract][Full Text] [Related]
20. Fragmentomics features of ovarian cancer.
Chao X; Kai Z; Wu H; Wang J; Chen X; Su H; Shang X; Lin R; Huang L; He H; Lang J; Li L
Int J Cancer; 2024 May; ():. PubMed ID: 38769763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
